Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Advantest | Penguin Solutions | Tempus AI | |
|---|---|---|---|
| Moat rating | wide A disclosed share that rose while margin expanded. The FY2025 Annual Securities Report and Business Report (84th term, filed 2026-06-26) lists as FY2025 progress: 'Further expanded our market share in the semiconductor tester (ATE) market (CY2024: 58%; CY2025: 65%)', earned on net sales of ¥1,128,610 million at an operating income to net sales ratio of 44.2%, 'an increase of 14.9 percentage points from the previous fiscal year'. The share is a company metric and the filing says so — 'the ratio of Advantest's semiconductor tester sales to the overall size of the semiconductor tester market', where 'The semiconductor tester market size is estimated independently by Advantest based on certain assumptions and available information'. The same filing names seven principal tester competitors (Teradyne, Inc., CCTech, Accotest, YC Corp., Cohu, Inc., UniTest Co., Ltd. and EXICON Ltd.), so this is a lead held against a named field rather than an empty one. | none The FY2025 10-K (fiscal year ended August 29, 2025) documents design-in niches but no durable excess return. In favour: the Competition section says some large rivals 'tend to have limited customization and service capabilities and are generally focused on higher-volume memory, storage, or compute products that are manufactured to industry-standard specifications'. It says the company's 'close collaboration with customers, customer-specific designs, long-lifecycle solutions, superior products and proprietary supply chain services create significant customer loyalty that may provide an advantage when competing against large international companies'. Against: the same filing says many competitors have 'substantially greater financial, technical, marketing, distribution and other resources' and 'lower cost structures'. Sales are made 'primarily pursuant to customer purchase orders and are not based on long-term supply agreements', and 'customers are not obligated to purchase our products even if we achieve a design win'. Large customers 'have exerted' pressure for price concessions, and the ten largest were 66% of fiscal 2025 net sales. GAAP operating income was 0.6%, 1.6% and 4.2% of net sales in fiscal 2023, 2024 and 2025, and fiscal 2024 had a net loss from continuing operations of $41.8 million. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) adds that Advanced Computing nine-month sales fell 20.6%, reflecting 'both the ongoing Penguin Edge wind down and hyperscale hardware sales in 2025 that did not recur in 2026'. The filing's own advantage claim is hedged ('may provide an advantage'): design-in niches exist, but the 10-K shows no durable excess return. | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." |
| Moat type | intangibles ip What management itself names as the source of the position is a proprietary platform. The July 29, 2026 Q1 FY2026 results briefing states: 'Our leading SoC Test platform, V93000, has been widely adopted across a broad range of customers in the increasingly complex AI semiconductor markets, where advanced packaging technologies including GPUs, ASICs, and CPUs are being adopted. It serves as a key foundation that underpins our competitive advantage.' The 84th-term report shows the spend behind it: R&D was approximately ¥71.4 billion in FY2024 and ¥78.1 billion in FY2025, 'The number of employees in its research and development division is approximately 30% of the Advantest workforce', and in the Test System Business Segment 'a large and ongoing investment in research and development is necessary in order to maintain market competitiveness'. Its stated IP mitigation is that 'Advantest strategically and proactively files patent applications during product development and prior to product shipment'. | none The strongest candidate moat source in the 10-K is design-in and qualification, a switching-cost argument, and the filing limits it too far to count. The risk factors say 'Our products are often incorporated into customers' systems at the design stage', and many specialty products 'are specifically designed for our OEM customers' systems or products'. But qualification is 'both product-specific and platform-specific', so a design win covers one platform. The filing notes that customers 'sometimes require us to re-qualify our products' for new platforms, which 'can be time-consuming and cause reductions in our net sales', so each new platform reopens the socket. It also says 'customers are not obligated to purchase our products even if we achieve a design win', and warns that OEMs designing in 'standardized or commodity components' could reduce demand for its 'higher priced specialized or customized solutions'. Scale is ruled out because the filing says many competitors have lower cost structures. Patents are ruled out as a durable source. The company holds about 1,650 of them and calls intellectual property 'an important aspect of our business', but it says its patents 'do not cover all of our technologies' and that competitors 'may design around our patented technologies'. It also says some products are 'built around mature industry standards and have less patent protection', so 'we cannot prevent our competitors from reverse-engineering and duplicating those products'. | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. |
| Leadership | clear leader The 84th-term report discloses Advantest's tester-market share at 65% in CY2025, up from 58% in CY2024, and carries the same 65% among its disclosed management metrics against a target of '58% or more'; the filing defines it as Advantest's semiconductor tester sales over a market size 'estimated independently by Advantest based on certain assumptions and available information'. The July 29, 2026 briefing names the platform behind that share — V93000, 'widely adopted across a broad range of customers in the increasingly complex AI semiconductor markets'. Teradyne, Inc. heads the filing's list of principal tester competitors. | at parity The 10-K claims no share figure or rank in any segment. It says 'Our businesses compete with numerous global and local companies'. Its HPC and AI business 'competes primarily with global manufacturers of HPC and AI products and services'. For fault-tolerant solutions it says 'we primarily compete with manufacturers of enterprise servers and industrial computers'. Its memory business competes 'against memory module providers and, to a lesser extent, large semiconductor manufacturers'. The risk factors warn that larger competitors 'may be able to respond better to new or emerging technologies, such as generative AI'. Against that, the company's stated edge is customization and service, where it says some large rivals 'tend to have limited customization and service capabilities'. Its leadership language is self-description without share figures: Cree LED 'has been a leader in LED lighting technology', Stratus Technologies is 'a global leader in simplified, protected and autonomous computing platforms and services', and the memory business is 'a primary supplier of longer-lifecycle solutions to OEM customers'. A specialist that claims no rank and faces many larger, lower-cost rivals, while neither leading nor clearly trailing in its niches, is parity. | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. |
| Pricing power | strong Q1 FY2026 gross profit was ¥255,553 million on net sales of ¥367,473 million, and the July 29, 2026 briefing states the resulting figure itself: 'Gross margin reached 69.5%', with 'an operating margin of 51.7%'. Management attributes that level to 'a favorable sales mix and limited inventory valuation losses amid the robust demand environment', not to price, and guides FY2026 full-year gross margin to 66–67% and operating margin to 49.4% after incorporating 'the impact of higher component costs, particularly for memory-related components'. FY2025 closed at a 44.2% operating margin, up 14.9 points year on year, on sales up 44.7%. | weak The FY2025 10-K describes price as set by customers and the market. It says its large customers 'are able to exert, have exerted and we expect will continue to exert, pressure on us to make concessions on price and on terms and conditions'. It says 'The markets for our Integrated Memory products have historically been characterized by declines in average selling prices', and that 'Competitive pressure has led in the past and may continue to lead to intensified price competition resulting in lower net sales and lower profit margins'. Gross margin held in a narrow band: 28.8% in fiscal 2023, 29.1% in fiscal 2024 and 28.8% in fiscal 2025. The filing attributes each move to mix, for example higher-margin Advanced Computing service revenue in 2024, not to pricing. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) reports gross margin of 27.8% versus 29.3% a year earlier (27.7% versus 28.9% for nine months), which it attributes to the Penguin Edge wind-down and sales mix. Third-quarter Integrated Memory sales rose 111.4% (75.6% for nine months) as 'accelerating AI-driven demand drove favorable pricing and increased volume', and the 10-Q says that business has 'gross margins which are lower than the Company average'. | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). |
| Summary | Advantest sells the test step that certifies silicon before it ships, and its position there is disclosed rather than inferred: its own tester-market-share metric moved from 58% in CY2024 to 65% in CY2025 (84th-term Annual Securities Report), against a market size the filing says Advantest estimates itself. The lead is concentrated in SoC test — the July 29, 2026 briefing calls V93000 'our leading SoC Test platform' and 'a key foundation that underpins our competitive advantage' — and the customer base runs straight into the AI chain: NVIDIA International, Inc. was ¥228,273 million, or 20.2%, of FY2025 consolidated net sales, having been below the filing's 10% disclosure threshold the prior year, with Taiwan Semiconductor Manufacturing Co., Ltd. at ¥124,922 million, or 11.1%. Economics moved with it: FY2025 operating margin was 44.2%, up 14.9 points, and Q1 FY2026 gross margin reached 69.5%, which management attributes to 'a favorable sales mix and limited inventory valuation losses amid the robust demand environment' rather than to price. The counterweights sit in the same documents. The 84th-term report's customer-trust risk factor warns that if Advantest fails to meet expectations on ramp-up and post-sales service, 'the maintenance or expansion of Advantest's market share may be constrained'; it names separate competitor sets in test handlers (Hon. Precision, CCTech, Cohu, TechWing) and device interfaces (TSE, ISC, BeLINK) where no share is disclosed at all; and the July 29, 2026 briefing guides FY2026 full-year gross margin down to 66–67% having 'incorporated the impact of higher component costs, particularly for memory-related components, mainly in the second half of the fiscal year'. | Penguin Solutions (formerly SMART Global Holdings) has three reportable segments per the FY2025 10-K. Advanced Computing ($648.4 million of fiscal 2025 net sales) designs, builds, deploys and manages AI and HPC clusters under OriginAI with the ICE ClusterWare software, and sells Stratus fault-tolerant servers. Integrated Memory ($464.2 million) sells SMART Modular specialty DRAM, flash and CXL memory and supply-chain services. Optimized LED ($256.1 million) sells Cree LED chips and components. Its advantage is customization rather than size. The filing says its memory business collaborates with OEMs 'throughout their design process across multiple projects' and is 'a primary supplier of longer-lifecycle solutions to OEM customers' in industrial, government, networking and enterprise markets. Its products must pass product- and platform-specific qualification, and some large rivals focus on higher-volume, industry-standard products. The limits are just as clear. Many competitors are larger and have lower cost structures. Customers buy on purchase orders, the ten largest were 66% of fiscal 2025 sales, and they 'have exerted' pressure for price concessions. Integrated Memory has historically seen declining average selling prices. AI hardware revenue is project-driven: Advanced Computing sales fell 26.0% in fiscal 2024 on 'the unpredictable nature of large project engagements'. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) says the AI infrastructure business is 'transitioning from a hyperscaler concentration toward a more diversified non-hyperscaler customer base across enterprise, neocloud, and sovereign AI', which 'may negatively impact our net sales during the transition'. The result is a set of design-in niches rather than a franchise, with an AI business that must keep re-winning large deployments. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. |
| Chain position | Back-end capital equipment: Advantest's testers certify devices after fabrication, and the 84th-term report's FY2025 major-customer table puts NVIDIA International, Inc. at 20.2% and Taiwan Semiconductor Manufacturing Co., Ltd. at 11.1% of consolidated net sales, with overseas sales 97.8% of the total. | Downstream integrator. Per the 10-K it buys memory from Samsung, Micron, SK hynix and Kioxia and processors from Intel and AMD, and turns them into specialty memory modules and managed AI/HPC clusters for OEM, enterprise, government and cloud customers. | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.42 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. |